Skip to main content
. 2020 Dec 11;23(1):140–148. doi: 10.1016/j.neo.2020.11.010

Table 1.

Protein detection in patient tissue and U-RT1 cell block sections by immunohistochemistry and immunocytochemistry.

Antigen CLL Bone Marrow Lymphoma Stomach Lymphoma Lymph Node U-RT1
BCL-2 +++ +++ +++ +++
BCL6 +
CD5 +++ ++ +
CD10 +
CD20 +++ +++ +++ ++
CD23 +++ + +++
CD30 n.a. −/+
CD38 ++ +++ +++
CDK4 n.a. ++
CDK6 n.a.
MYC + ++ + +
Cyclin D1
IgD +++
IgM +++ +
Ki-67 ++ +++ +++ +++
MUM1 n.a. ++ ++
P16 n.a.
P53 n.a. n.a. n.a.
PAX-5 +++ +++ +++ +++
PD-L1 n.a. - + +
Rb n.a. n.a. n.a. +++
ZAP-70 n.a. +++

Immunohistochemistry panels for U-RT1, gastric lymphoma, lymphoma found in the lymph node, and the underlying chronic lymphatic leukemia all from the same patient. Standard CLL markers were used. The stains for P53 and Rb missing in the lymphomas are due to the amount of tumor tissue available. Results were evaluated as follows: no reaction (−), 30% cells positive (+), 30% to 70% cells positive (++), more than 70% cells positive (+++).

CLL = chronic lymphocytic leukemia.